Literature DB >> 27272445

Management of refractory autoimmune hemolytic anemia via allogeneic stem cell transplantation.

L Rotenstein1, A Nathan2, I Ghobrial3, J Antin3, A Parnes4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27272445     DOI： 10.1038/bmt.2016.152

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  15 in total

1.  Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients.

Authors:  Claudia Schöllkopf; Lars Kjeldsen; Ole Weiss Bjerrum; Hans Torben Mourits-Andersen; Johan Lanng Nielsen; Bjarne Egelund Christensen; Bjarne Anker Jensen; Bjarne Bach Pedersen; Ellen Birkerod Taaning; Tobias Wirenfeldt Klausen; Henrik Birgens
Journal:  Leuk Lymphoma       Date:  2006-02

2.  Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease.

Authors:  Alexander Röth; Andreas Hüttmann; Russell P Rother; Ulrich Dührsen; Thomas Philipp
Journal:  Blood       Date:  2009-04-16       Impact factor: 22.113

3.  Long-term response of refractory primary cold agglutinin disease to eculizumab therapy.

Authors:  Neha Gupta; Eunice S Wang
Journal:  Ann Hematol       Date:  2013-05-31       Impact factor: 3.673

Review 4.  Cold agglutinin disease.

Authors:  Paul L Swiecicki; Livia T Hegerova; Morie A Gertz
Journal:  Blood       Date:  2013-06-11       Impact factor: 22.113

5.  Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia.

Authors:  Steven P Treon; Christina K Tripsas; Kirsten Meid; Sandra Kanan; Patricia Sheehy; Stacey Chuma; Lian Xu; Yang Cao; Guang Yang; Xia Liu; Christopher J Patterson; Diane Warren; Zachary R Hunter; Barry Turnbull; Irene M Ghobrial; Jorge J Castillo
Journal:  Blood       Date:  2014-05-23       Impact factor: 22.113

6.  Complement deposition in autoimmune hemolytic anemia is a footprint for difficult-to-detect IgM autoantibodies.

Authors:  Elisabeth M Meulenbroek; Masja de Haas; Conny Brouwer; Claudia Folman; Sacha S Zeerleder; Diana Wouters
Journal:  Haematologica       Date:  2015-09-09       Impact factor: 9.941

7.  Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival.

Authors:  Richard J Kelly; Anita Hill; Louise M Arnold; Gemma L Brooksbank; Stephen J Richards; Matthew Cullen; Lindsay D Mitchell; Dena R Cohen; Walter M Gregory; Peter Hillmen
Journal:  Blood       Date:  2011-04-01       Impact factor: 22.113

8.  Allogeneic stem-cell transplantation in patients with Waldenström macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  Charalampia Kyriakou; Carmen Canals; Jan J Cornelissen; Gerard Socié; Roel Willemze; Norbert Ifrah; Hildegard T Greinix; Didier Blaise; Eric Deconinck; Augustin Ferrant; Anton Schattenberg; Jean-Luc Harousseau; Anna Sureda; Norbert Schmitz
Journal:  J Clin Oncol       Date:  2010-10-18       Impact factor: 44.544

9.  Primary chronic cold agglutinin disease: a population based clinical study of 86 patients.

Authors:  Sigbjørn Berentsen; Elling Ulvestad; Ruth Langholm; Klaus Beiske; Henrik Hjorth-Hansen; Waleed Ghanima; Jon Hjalmar Sørbø; Geir E Tjønnfjord
Journal:  Haematologica       Date:  2006-04       Impact factor: 9.941

10.  TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins.

Authors:  Ju Shi; Eileen L Rose; Andrew Singh; Sami Hussain; Nancy E Stagliano; Graham C Parry; Sandip Panicker
Journal:  Blood       Date:  2014-04-02       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.